Best Life Sciences Companies in Calgary, Canada
The 59 best Life Sciences companies in Calgary, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Resverlogix.
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Calgary
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Resverlogix Provider of small molecule BET-inhibitors for CV disease for treating diabetes | $129M | 69 mo ago | Public | 19 | — | 303 patents Epigenetic BET bromodomain inhibition combined with SGLT2 inhibition for cardiovascular and renal therapies | — |
| 2 | Oncolytics Biotech Develops oncolytic viruses for use as cancer therapeutics 48Patents top 29%Product top 30%Funding top 31%News top 33% All 11 signals ▾Patentstop 29% Producttop 30% Fundingtop 31% Newstop 33% Innovationtop 41% Moattop 41% Growthtop 47% Techtop 47% Talentbottom 49% Marketbottom 38% Globalbottom 37% Patents: 450 patents matched (strict assignee match) · 6 filings since 2022 vs 40 in 2017-21 Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 48/100 | $48M | 15 mo ago | Public | 29 | Matt Coffey President and Chief Executive Officer | 450 patents Oncolytic virotherapy and viral formulation for cancer immunotherapy | — |
| 3 | Orpyx Wearable devices for neuropathy patients and athletes 53Funding top 29%Growth top 35%Tech top 39%Product top 46% All 8 signals ▾Fundingtop 29% Growthtop 35% Techtop 39% Producttop 46% Talentbottom 49% Marketbottom 41% Globalbottom 37% Newsbottom 18% Funding: Raised $38.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $39M | 21 mo ago | Series B | 89 | Breanne Everett Co-Founder & CEO | — | — |
| 4 | Willow Bioscience Developer of precision fermentation technology producing natural ingredients for various markets | $37M | 28 mo ago | Public | 34 | — | — | 1 expansion |
| 5 | Zenith Epigenetics Developer of small molecule BET inhibitors for cancer and autoimmune disorders 21Moat top 28%Patents top 33%Innovation top 42%Funding top 50% All 9 signals ▾Moattop 28% Patentstop 33% Innovationtop 42% Fundingtop 50% Productbottom 47% Globalbottom 37% Marketbottom 28% Techbottom 28% Newsbottom 27% Moat: Editorial + unicorn rating 4/10 · IP moat: 187 patents Patents: 187 patents matched (strict assignee match) · 23 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $17M | 14 mo ago | Seed | 16 | — | 187 patents Patents concentrated in health & consumer products | — |
| 6 | Kent Imaging Provider of near-infrared imaging solutions for wound care | $15M | 64 mo ago | Series B | 33 | — | 30 patents Multispectral visible‑NIR imaging sensors for medical diagnostic imaging | 1 launch |
| 7 | Syantra Health Developer of a blood test device to detect breast cancer 53Talent top 23%AI top 30%Growth top 35%Funding top 39% All 8 signals ▾Talenttop 23% AItop 30% Growthtop 35% Fundingtop 39% Moattop 48% Techbottom 40% Globalbottom 36% Marketbottom 29% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 53/100 | $10M | 4 mo ago | Series A | 15 | Kenneth Fuh Co-Founder | — | — |
| 8 | Sunniva Developer of medical cannabis products | $10M | 81 mo ago | Public | 148 | Anthony Holler Founder & CEO | — | — |
| 9 | Imaging Dynamics Company Develops imaging technology | $9M | 117 mo ago | Public | 13 | — | 11 patents Advanced digital radiography: dual‑energy imaging, distortion correction, and noise reduction. | — |
| 10 | Providence Therapeutics Developer of mRNA-based therapeutics for cancer and covid-19 treatment 55Patents top 24%Moat top 32%Innovation top 35%Growth top 35% All 11 signals ▾Patentstop 24% Moattop 32% Innovationtop 35% Growthtop 35% Talenttop 38% Fundingtop 43% Marketbottom 49% Newsbottom 45% Globalbottom 43% Partnersbottom 35% Techbottom 29% Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $9M | 14 mo ago | Series A | 68 | Eric Marcusson Co-Founder | 54 patents Lipid nanoparticle platforms for nucleic acid vaccine delivery and therapeutic formulations | 1 launch |
| 11 | Fluid Biomed Developer of medical device to treat brain aneurysms | $6M | 18 mo ago | Series A | 11 | John Wong Co-Founder & CEO | 9 patents Bioabsorbable flow‑diverting scaffolds and compression systems for endovascular interventions | — |
| 12 | Nimble Science Developer of personalised medicine for gut health | $3M | 39 mo ago | Seed | 10 | Sabina Bruehlmann Co-Founder & CEO | 16 patents Ingestible gastrointestinal sampling and targeted drug delivery devices and analysis systems | 1 partnership · 2 awards |
| 13 | FluroTech Provider of fluorescence spectroscopy-based technology solutions | $3M | 26 mo ago | Public | 18 | Danny Longa Co-Founder & CEO | — | — |
| 14 | Onco-Innovations Developer of therapeutics for cancer treatment 35Funding top 39%Tech top 41%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 39% Techtop 41% Growthtop 45% Talentbottom 49% Marketbottom 31% Globalbottom 25% Funding: Raised $1.9M across 3 rounds · 3 rounds over 1 yrs (3.0/yr) Tech: 26 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 35/100 | $2M | 5 mo ago | Public | — | Thomas O Shaughnessy CEO | — | 2 partnerships |
| 15 | NeXtraction Operator of a biotechnology company providing extraction, purification, and formulation services | $2M | 67 mo ago | Seed | 9 | Mark S. Dolar CEO & President | — | — |
| 16 | Hemostemix Developer of autologous cell therapy for the treatment of ischemic diseases | $1M | 18 mo ago | Public | 13 | — | — | — |
| 17 | Nanalysis Corp. Manufactures of benchtop NMR spectrometers 74Patents top 22%News top 24%Growth top 25%Innovation top 29% All 10 signals ▾Patentstop 22% Newstop 24% Growthtop 25% Innovationtop 29% Moattop 38% Markettop 39% Partnerstop 40% Fundingtop 46% Techtop 46% Globalbottom 49% Patents: 80 patents matched (strict assignee match) · 39 filings since 2022 vs 17 in 2017-21 News: 15 BI events in 12 mo (of 96 tracked, 9 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 74/100 | $1M | 6 mo ago | Public | 107 | — | 80 patents Magnetic resonance hardware: magnet pole pieces, structures, and data acquisition systems. | — |
| 18 | Neuraura Developer of a platform for detecting electrophysiological brain data | $1M | 84 mo ago | Seed | 5 | Pierre Wijdenes Co-Founder & CEO | — | 2 awards |
| 19 | NuVessl Provides its patented nanotechnology encapsulation platform for delivering active ingredients | $945K | 76 mo ago | Seed | — | Gijs Koning Managing Director | 33 patents Lipid-based nanocarriers for enhanced cannabinoid loading and transdermal delivery | — |
| 20 | Health Logic Interactive Provider of a device for chronic kidney disease assessment | $906K | 62 mo ago | Public | — | David Barthel CEO | — | — |
| 21 | PsiloTec Health Solutions Developer and provider of mushroom-based products to treat mental health | $522K | 62 mo ago | Seed | — | Peter Silverstone CEO | — | — |
| 22 | XORTX Pharma Therapeutics for the treatment kidney diseases caused by improper uric acid metabolism. | $450K | 11 mo ago | Public | 3 | Allen Davidoff President and CEO | — | — |
| 23 | Asia Green Biotechnology International biotechnology company focused on the development and evaluation of various bio-technologies | $200K | 59 mo ago | Late Stage | — | David Pinkman CEO | — | — |
| 24 | CurveNote Cloud-based data sharing and collaborative tool for researchers and scientists | $125K | 60 mo ago | Seed | 4 | Rowan Cockett Co-Founder & CEO | — | 4 launchs |
| 25 | SolAeroMed Biophysical respiratory drugs and delivery devices | $101K | 127 mo ago | Early Stage | 5 | Tamer El Mays Co-Founder | 26 patents Inhaled vapor drug delivery systems and cyclodextrin-based pulmonary surfactant therapies | — |
Top 12 Life Sciences companies in Calgary
#1
Series A · Calgary, Alberta · founded 2013 · 15 employees$10.4Mraised▾
Developer of a blood test device to detect breast cancer. The company offers the Syantra DX device for blood-based cancer detection test that utilizes a combination of biomarkers and artificial intelligence-generated algorithms for molecular diagnostics. It captures and decodes changes in how the body is functioning. It enables earlier detection and effective treatment of cancer.
- Mar 2026Grant (prize money)$2.4M
- Sep 2024Series A$3.6M
- Jan 2022Series A$6.8M
- Jun 2021Seed—
#2
Public · Calgary, Alberta · founded 1998 · 29 employees$48.1Mraised▾
Oncolytics Biotech is a development-stage biotechnology company that develops oncolytic viruses for use as cancer therapeutics. The company's leading product, REOLYSIN, is developed from the reovirus. Oncolytics Biotech claims that the virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) and Oncoltics Biotech (US).
- Apr 2025Post IPO$20M
- Oct 2010Post IPO$24M
- Post IPO$4.1M
#3
Seed · Calgary, Alberta · founded 2013 · 16 employees$16.6Mraised▾
Zenith Epigenetics is a developer of small molecule BET inhibitors for cancer and autoimmune disorders. The company’s proprietary epigenetic drug discovery platform functions by inhibiting BET bromodomains. Its lead product, ZEN-3694, is a BET inhibitor developed for hematological malignancies and solid tumors including prostate cancer. It can be act as a single therapeutic solution for prostate cancer.
- May 2025Seed$1.5M
- Apr 2025Seed—
- Apr 2025Conventional Debt$320.8K
- Mar 2025Conventional Debt$185.2K
#4
Public · Calgary, Alberta · founded 2024$1.9Mraised▾
Developer of therapeutics for cancer treatment. It offers technology that targets solid tumours that improve patient outcomes and fight against cancer which include colorectal cancer, breast cancer and lung cancer.
- Jan 2026Post IPO$880K
- Jul 2025Post IPO$291.5K
- Jan 2025Post IPO$696.8K
#5
Series A · Calgary, Alberta · founded 2015 · 68 employees$8.5Mraised▾
Developer of mRNA-based therapeutics for cancer and covid-19 treatment. The company's mRNA vaccines are customized based on the patient's tumor-specific mutations to induce an immune response. It generates strong T-cell responses that aim to kill cancer cells and destroy tumors. Also, developed PTX-COVID19-B and PTX-COVID19-LT for covid-19 treatment.
- May 2025Conventional Debt$711.6K
- May 2025Series A$711.6K
- Mar 2025Series A$209.8K
- Jan 2025Series A$395.4K
#6
Public · Calgary, Alberta · founded 2009 · 107 employees$1Mraised▾
Manufactures of benchtop NMR spectrometers. The company develops and manufactures compact, portable, benchtop Magnetic Resonance Imaging and Spectroscopy products. The NMR instruments are used for teaching, biotech and pharma, polymer research, food science, synthetic chemistry, reaction monitoring/process analytical technology, mining and minerals, oil and gas, security and defense, cannabis, and more.
- Dec 2025Post IPO$1.8M
- Apr 2023Post IPO$2.2M
- Aug 2021Post IPO$1.4M
- Jun 2019Post IPO$1.5M
#7
Series B · Calgary, Alberta · founded 2010 · 89 employees$38.5Mraised▾
Wearable devices for neuropathy patients and athletes. It develops a sensor-based product, Orpyx SI, the sensory insoles with remote patient monitoring allows users to manage and prevent diabetic foot ulcers and limb loss through advanced foot sensor technology and real-time analytics. The insoles can fit above the shoe and capture pressure data from the user's feet. The pressure data is then wirelessly transmitted from the shoe inserts to a smartwatch. The smartwatch alerts the user at extreme pressure levels to modify their behaviour and avoid damage. The device can be used to track neuropathy and is FDA cleared. Other product lines include SurroSense Rx system, Orpyx LogR solution and SurroGai Rx system.
- Sep 2024Series B$20M
- Oct 2023Series A$11K
- Jul 2020Series A$5.6M
#8
Series A · Calgary, Alberta · founded 2012 · 11 employees$5.5Mraised▾
Developer of medical device to treat brain aneurysms. The company has developed a hybrid polymer-metal flow-diverting stent to cure brain aneurysms. Also, its proprietary stent delivery system is used to navigate to bypass the aneurysm under angiographic guidance.
- Dec 2024Series A$27M
- Aug 2021Seed$4.7M
- Feb 2020Seed$846.7K
#9
Public · Calgary, Alberta · founded 2012 · 3 employees$450Kraised▾
XORTX is a therapeutics company spun out from the University of Florida, with a focus on orphan disease markets such as rare kidney diseases caused by improper uric acid metabolism. Its drug pipeline includes therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Phase 1), and Diabetic Nephropathy (DN), which target the renin-angiotensin-aldosterone system (RAAS).
- Aug 2025Post IPO$83.3K
- Jun 2025Post IPO$925K
- Feb 2024Post IPO$1.8M
- Jan 2021Post IPO$6.1M
#10
Public · Calgary, Alberta · founded 1981 · 34 employees$36.9Mraised▾
Developer of precision fermentation technology producing natural ingredients for various markets. The company utilizes advanced science to produce ingredients for the health and wellness, food and beverage, and personal care sectors. It offers a platform and network of manufacturing partners to rapidly bring precision fermentation processes from lab to manufacturing scale. The company leverages expertise to deliver commercially relevant results, with a team of strain engineers, bioinformaticians, fermentation scientists, chemists, engineers, and business leaders. The platform provides the ability to scale production to meet client needs, offering a simpler supply chain than plant-based production.
- Feb 2024Post IPO$100K
- Nov 2020Post IPO$28.8M
- May 2019Post IPO$8.1M
#11
Public · Calgary, Alberta · founded 2006 · 13 employees$1.3Mraised▾
Developer of autologous cell therapy for the treatment of ischemic diseases. The lead product ACP-01 is an autologous cell therapy for the treatment of critical limb ischemia which is characterised by chronic, inadequate blood flow to limbs, resulting in tissue loss and gangrene.
- Jan 2025Post IPO$284.4K
- Sep 2023Post IPO$240.9K
- Jun 2023Post IPO$403.5K
- Jan 2020Post IPO$2.3M
#12
Public · Calgary, Alberta · founded 2001 · 19 employees$128.8Mraised▾
Resverlogix is a provider of small molecule BET-inhibitors for CV disease for treating diabetes. It is a late clinical-stage biopharma developing selective BET-inhibitors for CV disease in Diabetes patients. The company's lead candidate is Apabetalone (RVX-208), a first-in-class, small-molecule selective BET bromodomain inhibitor (selective to BRD4-BD2). The company has a proprietary epigenetics drug development platform and has identified additional compounds based on targeting BET (Bromodomain and extra-terminal Domain) proteins.
- Oct 2020Post IPO$10M
- Aug 2020Post IPO$2M
- Sep 2019Conventional Debt$12M
- Jun 2019Post IPO$11.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Calgary researches in biotechnology
University of Calgary leads Calgary's biotechnology research, focusing optimistically on neutrophil and immune mechanisms, with recent output surging and breakthrough findings dominating over concerns.
- University of Calgary24
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.